Medical Device & Healthcare Industry Trends — 2026-05-24

Top 5 Headlines Today

• Lunit: Surpasses 930,000 cumulative U.S. SaaS subscriptions; expectations rise for global digital pathology M&A.
• Lunit: Signs MOU with Severance Hospital for joint development and clinical application of medical AI foundation models.
• GiVita: Secures 4.5 billion KRW in Series A funding to upgrade digital healthcare services for pre-diabetes.
• FDA: Revises 2026 guidelines for AI and wearable device oversight to accelerate market entry for low-risk devices.
• Dong-A ST: Officially declares digital healthcare a core growth engine through partnerships with Medy-S, Mediwhale, and i-SENS.

Key Corporate Developments

Lunit — U.S. AI Subscription Business Expansion

• What’s happening: Lunit’s U.S. subscription-based AI solutions have topped 930,000 cumulative contracts. Analysts are watching for potential upside as the global digital pathology M&A market heats up.
• The Numbers: Over 930,000 cumulative SaaS contracts.
• Insight: Lunit’s move into a recurring revenue model marks a shift from one-off licensing to steady income. As digital pathology M&A activity grows, Lunit’s technology and clinical data make it an attractive acquisition target.

Lunit × Severance Hospital — Foundation Model MOU

• What’s happening: Lunit signed an MOU with Severance Hospital to co-develop and clinically apply medical AI foundation models, expanding its reach into major Korean hospitals.
• The Numbers: Severance Hospital is one of the largest tertiary hospitals in Korea, with over 2 million outpatients annually.
• Insight: This partnership moves beyond simple software supply; it creates a cycle of clinical data acquisition and AI refinement, providing crucial clinical evidence for global expansion.

Dong-A ST — Digital Healthcare as a Key Growth Driver

• What’s happening: Dong-A ST is expanding into the full spectrum of digital healthcare—from diagnosis to care—by collaborating with Medy-S, Mediwhale, and i-SENS.
• The Numbers: 3 partner companies (Medy-S, Mediwhale, i-SENS) with more collaborations under review.
• Insight: The integration of pharma and medical devices shows that the lines in the industry are blurring. For startups, teaming up with large pharmaceutical companies offers a faster route to market.

GiVita — 4.5 Billion KRW Series A for Pre-diabetes Care

• What’s happening: Digital healthcare startup GiVita secured 4.5 billion KRW in Series A funding to focus on digital services for pre-diabetic patients and the digitization of clinical protocols.
• The Numbers: 4.5 billion KRW in Series A funding.
• Insight: The preventive health market is growing quickly via B2B channels. Building an ecosystem that links clinicians and patient data paves the way for future telehealth and Digital Therapeutics (DTx) expansion.

MFDS · Policy · Regulation

Rare Disease Device Supply and AI Ad Regulations

• Details: The MFDS introduced a system for direct government supply of medical devices for rare diseases and included provisions to ban misleading AI-based expert advertisements.
• Impact: New government procurement routes provide revenue paths for smaller manufacturers. Ad regulations will force digital health platforms to rethink their content strategies.

End of 'Grace Period' for GMP Violations

• Details: The MFDS abolished the 'grace period' for selling IVD (in-vitro diagnostic) products if a manufacturer violates Good Manufacturing Practice (GMP) standards before the expiration of their certification.
• Impact: Companies can no longer rely on grace periods for delayed audits. Strict compliance is now mandatory to avoid immediate sales bans.

Innovative Medical Device 'Fast-Track' System

• Details: The government implemented a system allowing 'innovative medical devices' to be applied in clinical settings within as little as 80 days. 45 items were designated in 2025.
• Impact: Faster market entry will shorten ROI cycles for startups, though clinical adoption and health insurance reimbursement remain key hurdles.

Digital Health & AI Highlights

• Lunit: Scaling through both U.S. SaaS subscriptions and hospital partnerships.
• Dong-A ST Ecosystem: Combining AI fundus diagnostics (Mediwhale), continuous glucose monitoring (i-SENS), and remote monitoring (Medy-S).
• GiVita: Focusing on connecting the gap between offline medical protocols and digital patient management.

Global MedTech Context

• FDA Guidelines: 2026 revisions for AI and wearables lower barriers for low-risk devices, aiding Korean firms like Lunit and Vuno.
• Global M&A: Growing interest in digital pathology firms makes Korean AI companies potential targets or partners.
• FDA TEMPO Pilot: A risk-based autonomous regulation approach for chronic disease digital devices. Korean DTx firms should adjust their U.S. regulatory strategies accordingly.

Today’s Insight

The synergy of Lunit’s U.S. growth, FDA deregulation, and global M&A trends is creating a new "Permit-Subscribe-Exit" growth path for Korean AI firms. Meanwhile, the MFDS’s stricter quality control mandates mean that regulatory readiness is now a core competitive advantage. The concurrent move into the preventive market by both startups like GiVita and pharma giants like Dong-A ST signals a rapidly maturing ecosystem where partnership and competition coexist.

Weekly Checkpoints

• Monitor: Lunit and Severance Hospital’s development roadmap and clinical application schedule.
• Check: MFDS updates on the 'Innovative Medical Device' list for the first half of 2026.
• Track: Final publication and scope details of the FDA’s revised AI guidelines.

Reader Action Items

• Practitioners: Audit your GMP expiration dates and create risk mitigation plans for the post-grace period landscape.
• Investors: Compare Lunit’s U.S. SaaS growth rates with global digital pathology valuation multiples to refine your assessments.
• Founders: Prepare documentation for the MFDS 'Fast-Track' requirements and explore participation in the FDA TEMPO pilot program.